Direct oral anticoagulants in chronic kidney disease: an update.

ABSTRACT:

Purpose of review

Direct oral anticoagulants (DOACs) are variably eliminated by the kidneys rendering their use potentially problematic in patients with chronic kidney disease (CKD) or necessitating appropriate dose adjustment.

Recent findings

Both observational and limited randomized trial data for DOACs compared with no treatment or with warfarin for patients with atrial fibrillation on maintenance dialysis were recently published. In a randomized trial in patients on hemodialysis, there was no significant difference in vascular calcification between patients who received rivaroxaban with or without vitamin K2 or vitamin K antagonists. A randomized trial of apixaban versus warfarin was terminated owing to poor enrollment and preliminary results identified no difference in

SUBMITTER: Mavrakanas TA 

PROVIDER: S-EPMC7769201 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature